Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
Does insulin glargine (Lantus) change appetite or cravings? A physician-reviewed deep dive covering mechanisms, clinical trial data, patient reports, and practical management strategies.
Read clinical reviewA clinician-level review of insulin glargine (Lantus) use in autoimmune disease: immunogenicity, anti-insulin antibodies, type 1 diabetes, thyroid and adrenal co-morbidities, and ORIGIN trial data.
Read clinical reviewA clinical review of how insulin glargine (Lantus) affects bone mineral density, fracture risk, and bone metabolism in type 1 and type 2 diabetes, with primary-literature citations and dosing context.
Read clinical reviewA clinician-level review of the insulin glargine (Lantus) cancer risk signal, covering the 2009 observational studies, the ORIGIN trial, mechanistic data on IGF-1R activation, and current prescribing guidance.
Read clinical reviewA clinical deep-dive into insulin glargine's long-term cardiovascular effects, anchored in ORIGIN and post-ORIGIN trial data, with dosing context and physician guidance.
Read clinical reviewA clinician-reviewed deep dive into how insulin glargine (Lantus) affects cognitive function, covering the ORIGIN trial, glycemic variability, hypoglycemia risk, and the emerging science of brain insulin signaling.
Read clinical reviewA physician-level breakdown of compounded insulin glargine versus branded Lantus: bioequivalence data, FDA regulatory status, safety considerations, cost, and clinical decision-making for type 1 and type 2 diabetes.
Read clinical reviewA GRADE-level review of insulin glargine (Lantus) clinical evidence: ORIGIN, BEGIN, EDITION, and biosimilar trials graded for certainty, with ADA/AACE guideline positions and practical dosing guidance.
Read clinical reviewA thorough clinical review of insulin glargine (Lantus) effects on hair and skin, covering injection-site reactions, lipohypertrophy, lipoatrophy, and dermatologic considerations, with primary-literature citations and practical management guidance.
Read clinical reviewA physician-reviewed deep dive into how insulin glargine (Lantus) affects liver function, including AST/ALT changes, hepatic glucose output, fatty liver risk, and dosing considerations for patients with liver disease.
Read clinical reviewA clinician-level review of how insulin glargine (Lantus) affects mood, depression risk, hypoglycemia-driven anxiety, and quality of life in people with diabetes, with primary-literature citations throughout.
Read clinical reviewA clinician-level review of how insulin glargine (Lantus) affects glucose metabolism, fat oxidation, thermogenesis, and energy expenditure, drawing on ORIGIN and current ADA/AACE guidelines.
Read clinical reviewA clinical review of insulin glargine (Lantus) microdosing protocols, covering the evidence base, dose-titration frameworks, safety considerations, and what ORIGIN and ADA guidelines say about basal insulin optimization.
Read clinical reviewEvidence-based strategies for preserving skeletal muscle mass while using Lantus (insulin glargine) in type 1 and type 2 diabetes. Covers dosing, protein intake, resistance training, GLP-1 combinations, and key trial data including ORIGIN.
Read clinical reviewA clinician-level guide to insulin glargine (Lantus) dose adjustments, hypoglycemia risk, and de-prescribing decisions after bariatric surgery, with primary-literature citations throughout.
Read clinical reviewWhen and how to hold or reduce Lantus (insulin glargine) before surgery. Evidence-based perioperative dosing, timing, and glucose targets backed by ADA guidelines, ORIGIN trial data, and FDA labeling.
Read clinical reviewStopping Lantus (insulin glargine) abruptly can cause dangerous hyperglycemia, diabetic ketoacidosis, and other rebound effects. Learn the clinical evidence, safe discontinuation protocols, and what your care team should monitor.
Read clinical reviewA physician-level review of insulin glargine (Lantus) and kidney outcomes: ORIGIN trial data, GFR dosing thresholds, albuminuria effects, and how to compare glargine against GLP-1 agonists and SGLT2 inhibitors for patients with CKD.
Read clinical reviewA physician-reviewed, evidence-based guide on how and when to safely restart insulin glargine (Lantus) after acute illness, covering dose recalculation, monitoring protocols, and common pitfalls.
Read clinical reviewHow temperature, activity, diet, and daylight-driven physiology affect insulin glargine (Lantus) requirements across seasons, with evidence-based dosing strategies for clinicians and patients.
Read clinical reviewA clinician-level review of how insulin glargine (Lantus) affects sexual function in type 1 and type 2 diabetes, covering erectile dysfunction, libido, hormonal pathways, and practical management steps backed by primary literature.
Read clinical reviewA clinician-reviewed deep dive into how insulin glargine (Lantus) affects sleep architecture, nocturnal hypoglycemia, and sleep quality in type 1 and type 2 diabetes. Includes primary trial data, dosing guidance, and clinical recommendations.
Read clinical reviewBoard-reviewed protocols for traveling across time zones on Lantus (insulin glargine). Covers dose-timing adjustments, storage rules, hypoglycemia prevention, and a real-world decision framework for east- and westbound travel.
Read clinical reviewA clinician-reviewed, week-by-week guide to your first month on Lantus (insulin glargine): what happens to your blood glucose, how doses get adjusted, what side effects appear, and when to call your provider.
Read clinical review